Thesis (Ph.D)--University of Tennessee Health Science Center, 1998. / Title from title page screen (viewed on October 17 2008). Research advisor: Kay F. Engelhardt. Document formatted into pages (xi, 162 p. : ill.). Vita. Abstract. Includes bibliographical references (p.162).

Thesis (M.S.)--University of Michigan, 1996. / Includes bibliographical references.

Thesis (M.S.)--University of Michigan, 1996. / Includes bibliographical references.

Thesis (Ph. D.)--University of Washington, 1999. / Vita. Includes bibliographical references (leaves 111-118).

Orientador: Yasmin Rodarte Carvalho / Banca: Juliana Mazzonetto Teófilo / Banca: Ana Lia Anbinder / Banca: Adriana Aigotti Haberbeck Brandão / Banca: Horácio Faig Leite / Abstract: Due to the adverse effects of estrogen, new therapies have been proposed, such as soy isoflavones. However, their effects on bone repair and uterus epithelium remain unclear. The aim of this work was to study the acute effects of ovariectomy and treatment with estrogen and soy isoflavones, isolated or in association, on rat bone repair and uterus epithelium. 120 rats were used; 96 ovariectomized and 24 Sham-operated (SHAM). The ovariectomized rats were dibided into 4 groups, receiving orally: 1 mg/kg/day of 17 'beta'-estradiol valerate(OVZ-E); 15mg/kg/day of isoflavones (OVZ-I); associated treatments (OVZ-A); and vehile (OVZ). SHAM rats received vehicle. Treatment began on the ovariectomy day. The lower first molar was removed on both sides 15 days after ovariectomy. The rats received the treatment until sacrificed, which occurred at seven, 21 and 45 days after dental extraction. The uterus was submitted to histological analyses and the mandible to histological, histomorphometric, backscattered electron microscopy (BSE) and immunohistochemistry analyses. Concerning bone repair, no difference was observed in trabecular volume between the OVZ and SHAM groups for each period. Histological analysis and BSE revealed changes in bone microarchitecture after 45 days. Verification showed that the SHAM group presented a higher mean osteoid volume at seven days compared to the OVZ and OVZ-E groups and that the OVZ-A group showed the highest mean for this period. The number of mast cells tended to be higher in the OVZ group at 45 days. Strong expression of TGF-'beta' was observed at seven days, which diminished over time. The OVZ-E group presented the lowest mineral apposition rate at seven days. No difference was observed for the remaining periods. The SHAM, OVZ-E and OVZ-A... / Doutor

Although many women find relief from menopause through hormone therapy (HT), current guidelines recommend that HT be used only for short-term relief of symptoms. Women who attempt to stop HT often encounter troublesome recurrent symptoms leading to a diminished quality of life (QoL); 25% of women who discontinue eventually resume HT. Unfortunately, there is little information for women and their health care providers as to the best way to discontinue HT or how to prepare and guide women through this process. An in-depth description of women‘s experiences during HT discontinuation and the factors influencing recurrent symptoms, QoL and discontinuation outcome would provide knowledge to develop much needed counseling and support interventions. The purpose of this study was to explore women‘s experiences discontinuing hormone therapy for menopause. This Internet-based mixed-methods study used a dominant Qualitative Descriptive design with embedded quantitative QoL measurements. Participants completed the quantitative questionnaires online while open-ended questions were completed either online or by telephone. Interview data were analyzed through Qualitative Content Analysis; descriptive statistics were used to explore the quantitative measures. Participants were stratified by discontinuation status for comparison of variations in discontinuation experiences, QoL and influencing factors. Thirty-four women (20 stopped, 9 resumed, 4 tapering) were enrolled. One overarching theme--'a solitary journey'--emerged: although all women embarked on this journey, each woman traveled her own path. Two subthemes--'burden and interference' and 'appraising risk'--encompassed the symptom factors (severity, interference and sensitivity) that influenced women's experiences and the manner in which women evaluated their options. Other influencing factors included: readiness viii and reasons for stopping HT, beliefs about menopause and roles. QoL was strongly connected to symptoms for many but not all women. Information from health care providers was inconsistent; women desired more support from providers and other women. The rich description of women's experiences stopping HT highlights the need for providers to assess women's sensitivity to symptoms and readiness to discontinue to determine which women might benefit from more support. Greater health literacy would enhance women's understanding of HT risks. More research is needed on symptom clusters and interference and strategies for minimizing their impact.

Disputats, Linköping, 2006. / Med litteraturhenvisninger.

Wan Din. / Thesis (M.Phil.)--Chinese University of Hong Kong, 1997. / Includes bibliographical references (leaves 155-175). / ABSTRACT --- p.1 / ACKNOWLEDGMENTS --- p.3 / LIST OF TABLES --- p.5 / LIST OF FIGURES --- p.7 / LIST OF ABBREVIATIONS --- p.8 / Chapter I. --- INTRODUCTION --- p.9 / Chapter I.A. --- Menopause --- p.9 / Chapter I.A.1. --- Definition of the Menopause --- p.9 / Chapter I.A.2. --- Pathophysiology of Ovarian Failure --- p.10 / Chapter I.B. --- Effects of the Menopause --- p.13 / Chapter I B.1. --- Acute Effects --- p.13 / Chapter I.B.2. --- Medium Term Effects --- p.14 / Chapter I.B.3. --- Chronic Effects --- p.15 / Chapter I.B.3.a. --- Osteoporosis --- p.15 / Chapter I.B.3.b. --- Coronary Artery Disease (CAD) --- p.17 / Chapter I.C. --- Management of the Menopause --- p.19 / Chapter I.C.1. --- Hormone Replacement Therapy --- p.21 / Chapter I.C.2. --- Oestrogens --- p.22 / Chapter I.C.2.a. --- Oral Oestrogens --- p.22 / Chapter I.C.3. --- Progestogens --- p.24 / Chapter I.C.3.a. --- Combined Oestrogen and Progestogen Therapy --- p.24 / Chapter I.C.4. --- Complications and Contraindications to Hormone Replacement Therapy --- p.26 / Chapter II. --- LITERATURE REVIEW --- p.34 / Chapter II.A. --- Atherosclerosis --- p.35 / Chapter II.B. --- Risk Factors for Coronary Artery Disease --- p.37 / Chapter II.B.1. --- Age and Sex --- p.38 / Chapter II.B.2. --- Age at Menopause --- p.38 / Chapter II.B.3. --- Family History --- p.38 / Chapter II.B.4. --- Serum Lipids --- p.39 / Chapter II.B.5. --- Blood Pressure --- p.39 / Chapter II.B.6. --- Smoking --- p.40 / Chapter II.B.7. --- Diabetes Mellitus --- p.40 / Chapter II.C. --- The Effect of the Menopause on Risk Factors for Coronary Heart Disease --- p.41 / Chapter II.C.1. --- The Effect of the Menopause on Lipids and Lipoproteins --- p.41 / Chapter II.C.2. --- The Effect of the Menopause on Glucose and Insulin Metabolism --- p.43 / Chapter II.C.3. --- The Effect of the Menopause on Coagulation --- p.44 / Chapter II.C.4. --- The Effect of the Menopause on the Arterial Wall --- p.45 / Chapter II.D. --- The Risk of Coronary Artery Disease After the Menopause --- p.46 / Chapter II.D.1. --- The Effect of the Menopause on Peripheral Vascular Disease (PVD) --- p.47 / Chapter II.E. --- The Effect of the Hormone Replacement Therapy on Coronary Artery Disease Risk --- p.49 / Chapter II.F. --- The Mechanism of Cardioprotection of Oestrogen --- p.63 / Chapter II.F.1. --- The Indirect Effect of the Hormone Replacement Therapy on the Cardiovascular System --- p.64 / Chapter II.F.1.a. --- The Effect on Lipids and Lipoproteins --- p.64 / Chapter II.F.1.b. --- The Effect on Coagulation and Fibrinolysis --- p.66 / Chapter II.F.1.c. --- The Effect on Insulin and Glucose Metabolism --- p.67 / Chapter II.F.2. --- The Direct Effects of the Hormone Replacement Therapy on the Cardiovascular System --- p.67 / Chapter II.F.2.a. --- The Effect of Oestrogen on Vascular Contractility --- p.68 / Chapter II.F.2.b. --- The Effect of Oestrogen on Endothelial Dysfunction --- p.69 / Chapter II.F.2.C. --- Other Possible Direct Actions of Oestrogen --- p.72 / Chapter II.G. --- The Effects of Oestrogen on Blood Flow --- p.73 / Chapter III. --- RESEARCH PLAN --- p.78 / Chapter III.A. --- Formation of Research Hypothesis --- p.78 / Chapter III B. --- Research Hypothesis --- p.80 / Chapter III.C. --- Plan of Studies --- p.81 / Chapter III.C.1. --- Pilot Study --- p.81 / Chapter III.C.2. --- Randomized Controlled Study --- p.81 / Chapter IV. --- METHODOLOGY --- p.84 / Chapter IV.A. --- Pilot Study --- p.84 / Chapter IV.B. --- Study Population --- p.87 / Chapter IV.B.1. --- Recruitment of Cases --- p.88 / Chapter IV.B.1.a. --- Patients' Consent --- p.88 / Chapter IV.B.1.b. --- Method of Recruitment --- p.88 / Chapter IV.B.1.e. --- Research Methodology --- p.89 / Chapter IV.C. --- Ethical Considerations --- p.90 / Chapter IV.D. --- Samples Size Calculation --- p.92 / Chapter IV.E. --- Statistical Analysis --- p.93 / Chapter IV.F. --- Physical Principles of the Measurement of Peripheral Resistance --- p.94 / Chapter IV.F.1. --- The Arterial Analogue Waveform --- p.97 / Chapter IV.F.2. --- Peak Systolic Velocity --- p.98 / Chapter IV.G. --- Measurement of Pulsatility Index --- p.100 / Chapter IV.G.1. --- Establishment of Methodologies Used to Measure Peripheral Blood Flow --- p.105 / Chapter IV.G.2. --- Training of the Investigator --- p.107 / Chapter IV.H. --- Assay for Serum Oestradiol --- p.108 / Chapter IV.H.1. --- Principles --- p.108 / Chapter IV.H.2. --- Reagents --- p.109 / Chapter IV.H.3. --- Sample Dilution --- p.111 / Chapter IV.H.4. --- Calibration --- p.112 / Chapter IV.H.5. --- Quality Control --- p.112 / Chapter IV.H.6. --- Assay Validation --- p.113 / Chapter V. --- RESULTS --- p.115 / Chapter V.A. --- Pilot Study --- p.115 / Chapter V.B. --- Study Population --- p.118 / Chapter V.B.1. --- Characteristics of the Patients at Recruitment --- p.120 / Chapter V.B.2. --- Doppler Measurements --- p.123 / Chapter V.B.3. --- Pulsatility Index and Serum Oestradiol --- p.135 / Chapter VI. --- DISCUSSION --- p.137 / Chapter VI.A. --- Overview --- p.132 / Chapter VI.A.1. --- The Pilot Study --- p.133 / Chapter VI.B. --- Study Population --- p.136 / Chapter VI.C. --- Doppler Ultrasound as a Measurement of Vascular Resistance and Blood Flow --- p.142 / Chapter VI.C.1. --- Reliability of Doppler Study --- p.143 / Chapter VI.D. --- Pulsatility Index and Hormone Replacement Therapy --- p.146 / Chapter VI.E. --- Effects of Oestrogen on Pulsatility Index --- p.150 / Chapter VI.F. --- Conclusions --- p.152 / Chapter VI.G. --- Future Directions --- p.153 / REFERENCES --- p.155 / APPENDIX1 --- p.176

Made available in DSpace on 2014-06-11T19:30:59Z (GMT). No. of bitstreams: 0 Previous issue date: 2007-07-10Bitstream added on 2014-06-13T21:01:51Z : No. of bitstreams: 1 silveira_vas_dr_sjc.pdf: 653051 bytes, checksum: 288edba1011b8bcc5a34ac57d1a5bbfb (MD5) / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / Due to the adverse effects of estrogen, new therapies have been proposed, such as soy isoflavones. However, their effects on bone repair and uterus epithelium remain unclear. The aim of this work was to study the acute effects of ovariectomy and treatment with estrogen and soy isoflavones, isolated or in association, on rat bone repair and uterus epithelium. 120 rats were used; 96 ovariectomized and 24 Sham-operated (SHAM). The ovariectomized rats were dibided into 4 groups, receiving orally: 1 mg/kg/day of 17 'beta'-estradiol valerate(OVZ-E); 15mg/kg/day of isoflavones (OVZ-I); associated treatments (OVZ-A); and vehile (OVZ). SHAM rats received vehicle. Treatment began on the ovariectomy day. The lower first molar was removed on both sides 15 days after ovariectomy. The rats received the treatment until sacrificed, which occurred at seven, 21 and 45 days after dental extraction. The uterus was submitted to histological analyses and the mandible to histological, histomorphometric, backscattered electron microscopy (BSE) and immunohistochemistry analyses. Concerning bone repair, no difference was observed in trabecular volume between the OVZ and SHAM groups for each period. Histological analysis and BSE revealed changes in bone microarchitecture after 45 days. Verification showed that the SHAM group presented a higher mean osteoid volume at seven days compared to the OVZ and OVZ-E groups and that the OVZ-A group showed the highest mean for this period. The number of mast cells tended to be higher in the OVZ group at 45 days. Strong expression of TGF-'beta' was observed at seven days, which diminished over time. The OVZ-E group presented the lowest mineral apposition rate at seven days. No difference was observed for the remaining periods. The SHAM, OVZ-E and OVZ-A...

Thesis (Ph. D.)--University of Washington, 2001. / Vita. Includes bibliographical references (leaves 103-131).